Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02696993 · ClinicalTrials.gov registry record · Phase 1
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
A Phase 1 study of Metastatic Malignant Neoplasm in the Brain and Stage IV Non-Small Cell Lung Cancer AJCC v7, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02696993 is a Phase 1 study of Metastatic Malignant Neoplasm in the Brain and Stage IV Non-Small Cell Lung Cancer AJCC v7 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, roughly in line with the 86-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02696993, a Phase 1 study of Metastatic Malignant Neoplasm in the Brain and Stage IV Non-Small Cell Lung Cancer AJCC v7, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the side effects and best dose of nivolumab when giving together with stereotactic radiosurgery or whole brain radiotherapy with or without ipilimumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to the brain. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Radiation therapy, such as whole-brain radiotherapy, uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab together with stereotactic radiosurgery or whole brain radiotherapy with or without ipilimumab may work better in treating patients with non-small cell lung cancer that has spread to the brain.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
- RADIATION Stereotactic Radiosurgery
- PROCEDURE Cognitive Assessment
- BIOLOGICAL Ipilimumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02696993
The ClinicalTrials.gov registry entry for NCT02696993 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 86-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02696993 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02696993 about?
NCT02696993 is a clinical study titled "Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer". This phase I/II trial studies the side effects and best dose of nivolumab when giving together with stereotactic radiosurgery or whole brain radiotherapy with or without ipilimumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to the brain. Monocl...
What is the current status of trial NCT02696993?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2016-12-16. Estimated completion is 2027-12-31.
What conditions does trial NCT02696993 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7.
What interventions are being tested in trial NCT02696993?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Stereotactic Radiosurgery (RADIATION), Cognitive Assessment (PROCEDURE), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02696993?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02696993 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
RECRUITING · Phase 1
-
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Malignant Neoplasm in the Brain
All registered trials for this condition
Stage IV Non-Small Cell Lung Cancer AJCC v7
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.